Drug Profile
AX 024
Alternative Names: AX-024; AX-024.HClLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Artax Biopharma
- Class Antiasthmatics; Small molecules
- Mechanism of Action Nck protein modulators; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Asthma(In volunteers) in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in United Kingdom (PO)
- 01 Jan 2016 Artax Biopharma completes a phase I trial in Healthy volunteers in United Kingdom (NCT02546635)